Anorectic state of obesity medications in the United States. Are leaner times ahead?
Expert Opin Pharmacother · 2020
Last updated 2026-05-28Obesity affects 40% of people in the U.S., but prescription weight-loss medications are rarely used despite five options currently available. Several new medications are in late-stage clinical trials, but it remains uncertain whether these future treatments will fully address the country’s obesity healthcare needs.
AI summary of the abstract below.
| Journal | Expert Opin Pharmacother, 2020 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.27 |
| NIH percentile | 17 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management.: This special report provides an overview of the emerging obesity pharmacotherapies based on the data available from recruiting and active phase II/III trials from a registry of clinical trials. The authors also give their expert opinion and provide their future perspectives on the treatment of obesity based on what is known.: Despite obesity being a chronic condition affecting 40% of the US population, there is a low demand for obesity medications in the US market. Although the potential obesity medications that are currently being investigated in phase II/III clinical trials are promising, it is unclear whether the future pharmacotherapies will be enough to meet the health care need.
Verbatim abstract via PubMed 31762335 ↗